Shares of Regeneron Pharmaceuticals (REGN) were lower Monday after The Food and Drug Administration put a drug study on hold. Regeneron and partner Teva Pharmaceutical Industries (TEVA) had been in a mid-stage study of their experimental drug for chronic lower back pain. As a result of the FDA's decision, Regeneron has completed an unplanned interim review of data and has stopped dosing patients. But the two drugmakers plan to discuss with the FDA a late-stage study for chronic lower back pain.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.